IP Library › Granted Patent US 12,421,233
Granted Patent B2
US 12,421,233 · App. 19/038,543 · Granted Sep 23, 2025

WRN inhibitors

Inventors: Derun Li (Boston, MA); Angela V. West (Franklin, MA); Justin Caravella (Cambridge, MA); Nathan E. Genung (Boston, MA); Florian Bartels (Berlin, DE); Robert Lee Dow (Groton, CT); Silvana Marcel Leit de Moradei (Burlington, MA); Nikolay Sitnikov (Berlin, DE)
Assignee: Nimbus Wadjet, Inc.
C07D471/04A61K31/4985A61K31/501A61K31/506A61K31/53A61K31/5377A61K31/551C07D471/14C07D491/147C07D495/14C07D513/14C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,233
App. No.
19/038,543
Granted
Sep 23, 2025
Kind
B2
Abstract

The present disclosure is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.

Claims (34)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein the compound is:

9. The compound of claim 1 , wherein the compound is:

10. The compound of claim 1 , wherein the compound is:

11. The compound of claim 1 , wherein the compound is:

12. The compound of claim 1 , wherein the compound is:

13. The compound of claim 1 , wherein the compound is:

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant, or vehicle and a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition of claim 14 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition of claim 14 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition of claim 14 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

18. The pharmaceutical composition of claim 14 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

19. The pharmaceutical composition of claim 14 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

20. The pharmaceutical composition of claim 14 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (11)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: WEST, ANGELA V.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 070264/0837 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: CARAVELLA, JUSTIN
To: NIMBUS DISCOVERY, INC.
Reel/Frame 070264/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: GENUNG, NATHAN E.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 070264/0923 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: BARTELS, FLORIAN
To: NUVISAN ICB GMBH
Reel/Frame 070264/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: DOW, ROBERT LEE
To: BIOPHARMAWORKS, LLC
Reel/Frame 070264/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: LEIT DE MORADEI, SILVANA MARCEL
To: NIMBUS DISCOVERY, INC.
Reel/Frame 070265/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: SITNIKOV, NIKOLAY
To: NUVISAN ICB GMBH
Reel/Frame 070265/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: NUVISAN ICB GMBH
To: NIMBUS DISCOVERY, INC.
Reel/Frame 070265/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: BIOPHARMAWORKS, LLC
To: NIMBUS DISCOVERY, INC.
Reel/Frame 070265/0226 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: LI, DERUN
To: NIMBUS DISCOVERY, INC.
Reel/Frame 070268/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: NIMBUS DISCOVERY, INC.
To: NIMBUS WADJET, INC.
Reel/Frame 070268/0857 →
Continuity (8)
Continuation 18738470 · Jun 10, 2024
Provisional Application 63639457 · Apr 26, 2024
Provisional Application 63566038 · Mar 15, 2024
Provisional Application 63613647 · Dec 21, 2023
Provisional Application 63586952 · Sep 29, 2023
Provisional Application 63519746 · Aug 15, 2023
Provisional Application 63507014 · Jun 8, 2023
Related Publication 20250171442A1 · May 29, 2025
References Cited (75)
US 11530413B2 · Billy et al. · 2022 [cited by applicant]
US 11878973B2 · Bordas et al. · 2024 [cited by applicant]
US 20050234091A1 · Regan et al. · 2005 [cited by applicant]
US 20060131761A1 · Chauhan et al. · 2006 [cited by applicant]
US 20100093716A1 · Gilchrest et al. · 2010 [cited by applicant]
US 20100137279A1 · Cheng et al. · 2010 [cited by applicant]
US 20140206679A1 · Cheng et al. · 2014 [cited by applicant]
US 20210163423A1 · Qian et al. · 2021 [cited by applicant]
US 20220133693A1 · Vazquez et al. · 2022 [cited by applicant]
US 20230046859A1 · Bordas et al. · 2023 [cited by applicant]
US 20240140954A1 · Zhuo et al. · 2024 [cited by applicant]
US 20240245694A1 · Bordas et al. · 2024 [cited by applicant]
CN 117964558A · 2024 [cited by applicant]
CN 118459466A · 2024 [cited by applicant]
CN 118684677A · 2024 [cited by applicant]
CN 118684678A · 2024 [cited by applicant]
CN 118994204A · 2024 [cited by applicant]
CN 119019407A · 2024 [cited by applicant]
CN 119161363A · 2024 [cited by applicant]
WO WO2018229683A1 · 2018 [cited by applicant]
WO WO2019016772A2 · 2019 [cited by applicant]
WO WO2021178920A1 · 2021 [cited by applicant]
WO WO2022249060A1 · 2022 [cited by applicant]
WO 2023208092A1 · 2023 [cited by applicant]
WO WO2024079623A1 · 2024 [cited by applicant]
WO WO2024105553A1 · 2024 [cited by applicant]
WO WO2024105610A1 · 2024 [cited by applicant]
WO WO2024110853A1 · 2024 [cited by applicant]
WO WO2024120378A2 · 2024 [cited by applicant]
WO WO2024140597A1 · 2024 [cited by applicant]
WO WO2024140714A1 · 2024 [cited by applicant]
WO WO2024153155A1 · 2024 [cited by applicant]
WO WO2024153244A1 · 2024 [cited by applicant]
WO WO2024155884A1 · 2024 [cited by applicant]
WO WO2024187049A1 · 2024 [cited by applicant]
WO WO2024193683A1 · 2024 [cited by applicant]
WO WO2024193716A1 · 2024 [cited by applicant]
WO WO2024199108A1 · 2024 [cited by applicant]
WO WO2024199109A1 · 2024 [cited by applicant]
WO WO2024220887A1 · 2024 [cited by applicant]
WO WO2024222677A1 · 2024 [cited by applicant]
WO WO2024230828A1 · 2024 [cited by applicant]
WO WO2024235292A1 · 2024 [cited by applicant]
WO WO2024246862A1 · 2024 [cited by applicant]
WO WO2024246863A1 · 2024 [cited by applicant]
WO WO2024254511A2 · 2024 [cited by applicant]
WO WO2024254602A1 · 2024 [cited by applicant]
WO WO2024255765A1 · 2024 [cited by applicant]
WO WO2024255790A1 · 2024 [cited by applicant]
WO WO2024259048A2 · 2024 [cited by applicant]
WO 2025002413A1 · 2025 [cited by applicant]
WO 2025014846A1 · 2025 [cited by applicant]
WO 2025014877A2 · 2025 [cited by applicant]
WO 2025021148A1 · 2025 [cited by applicant]
WO 2025026382A1 · 2025 [cited by applicant]
WO 2025045145A1 · 2025 [cited by applicant]
WO 2025049746A1 · 2025 [cited by applicant]
WO 2025087274A1 · 2025 [cited by applicant]
Heuser et al., “Challenges for the Discovery of Non-Covalent WRN Helicase Inhibitors,” ChemMedChem. Apr. 16, 2024;19(8):e202300613. [cited by applicant]
Picco et al., “Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells,” Cancer Discov. Aug. 2, 2024;14(8):1457-1475. [cited by applicant]
Ferretti et al., “Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers,” Nature. May 2024;629(8011):443-449. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2024/033090, dated Sep. 6, 2024. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2024/025525, dated Aug. 13, 2024. [cited by applicant]
McDonald et al., “Project Drive: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell,” Jul. 27, 2017;170(3):577-592. [cited by applicant]
U.S. Appl. No. 18/766,189, filed Jul. 8, 2024. [cited by applicant]
National Center for Biotechnology Information. “3-(2-Methoxypyridin-4-yl)-5,6,7,8-tetrahydro [1,2,4]triazolo[4,3-a]pyrimidIne: Pubchem CID 136034193” Pubchem entry (online), pp. 1-9, Jan. 21, 2019; URL: https://pubchem.… [cited by applicant]
Pubchem, SID 248767314, Modify Date: Jan. 25, 2017 Retrieved from the Internet <URL: https://pubchem.ncbi.nlm.nih.gov/substance/248767314>. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2024/033732, dated Sep. 17, 2024. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2024/033276, dated Sep. 26, 2024. [cited by applicant]
Rico et al., “WRN Helicase Target Review: The Next Synthetic Lethality Drug Approval?” Drug Hunter, Mar. 5, 2025. [cited by applicant]
Pubchem, SID 438301, Modify Date: Dec. 19, 2011, Retrieved from the Internet <URL: https://pubchem.ncbi.nlm.nih.gov/substance/438301>. [cited by applicant]
Pubchem, SID 396355792, Modify Date: Dec. 6, 2019, Retrieved from the Internet <URL: https://pubchem.ncbi.nlm.nih.gov/substance/396355792>. [cited by applicant]
Boiko et al., “Preclinical Characterization of NTX-452, a Potent, Selective and Highly Efficacious WRN Inhibitor for the Treatment of MSI-H Tumors,” Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets an… [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2024/037061, dated Feb. 3, 2025. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2024/061505, dated Apr. 24, 2025. [cited by applicant]